Ultragenyx to Present at Upcoming Investor Conferences
- Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Cowen Annual Healthcare Conference on
Tuesday, March 12, 2019at 10 a.m. ETin Boston, MA. Tom Kassberg, the company’s Chief Business Officer, will present at the Barclays Global Healthcare Conferenceon Wednesday, March 13, 2019at 8 a.m. ETin Miami, FL.
The live and archived webcast of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.
Investors & Media
Source: Ultragenyx Pharmaceutical Inc.